Primary human organoids models: Current progress and key milestones

Front Bioeng Biotechnol. 2023 Mar 3:11:1058970. doi: 10.3389/fbioe.2023.1058970. eCollection 2023.

Abstract

During the past 10 years the world has experienced enormous progress in the organoids field. Human organoids have shown huge potential to study organ development, homeostasis and to model diseases in vitro. The organoid technology has been widely and increasingly applied to generate patient-specific in vitro 3D cultures, starting from both primary and reprogrammed stem/progenitor cells. This has consequently fostered the development of innovative disease models and new regenerative therapies. Human primary, or adult stem/progenitor cell-derived, organoids can be derived from both healthy and pathological primary tissue samples spanning from fetal to adult age. The resulting 3D culture can be maintained for several months and even years, while retaining and resembling its original tissue's properties. As the potential of this technology expands, new approaches are emerging to further improve organoid applications in biology and medicine. This review discusses the main organs and tissues which, as of today, have been modelled in vitro using primary organoid culture systems. Moreover, we also discuss the advantages, limitations, and future perspectives of primary human organoids in the fields of developmental biology, disease modelling, drug testing and regenerative medicine.

Keywords: disease modelling; organoids; primary organoids; primary tissue culture; regenerative medicine; three dimensional model.

Publication types

  • Review

Grants and funding

This work has been possible thanks to the support of the NIHR Great Ormond Street Hospital Biomedical Research Centre, the Wellcome Trust Innovative Engineering for Health Award (WT101957), OAK foundation (OCAY-14-191) and the Great Ormond Street Hospital Children’s Charity. BS is recipient of a personal fellowship from Politecnico di Milano. GGG is supported by the NIHR GOSH BRC funding. MFMG is supported by a H2020 Marie Skłowdoska-Curie Fellowship (Grant agreement 843265). PDC is supported by the National Institute for Healthcare and Research (NIHR-RP-2014-04-046).